Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
312 participants
INTERVENTIONAL
2025-01-10
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis
NCT00263315
Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics
NCT00421187
Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study
NCT00177710
Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.
NCT00775138
Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212
NCT02628600
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single drug group
Liposomal amphotericin B (AmBisome®)
Liposomal Amphotericin B
Liposomal amphotericin B (AmBisome®) alone
Combination therapy
Liposomal amphotericin B (AmBisome®) combination with Isavuconazole
Combination therapy group
Liposomal amphotericin B (AmBisome®) combination with Isavuconazole
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Combination therapy group
Liposomal amphotericin B (AmBisome®) combination with Isavuconazole
Liposomal Amphotericin B
Liposomal amphotericin B (AmBisome®) alone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals with Probable or proved PM, as indicated by clinical and radiological findings.
Exclusion Criteria
* Patients who have documented allergies to azoles or amphotericin B regimens
* Patients with serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or bilirubin levels exceeding five times the upper limit of normal (ULN).
* Patients with irreversible heart or liver failure, or those experiencing massive, fatal hemoptysis.
* Patients who have experienced a myocardial infarction or cerebral infarction.
* Patients currently receiving extracorporeal membrane oxygenation (ECMO) treatment.
* Pregnant or breastfeeding individuals. 8.Patients with individual reasons that may prevent them from completing the treatment protocol.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bin Cao
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bin Cao
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bin Cao
Role: PRINCIPAL_INVESTIGATOR
China-Japan Friendship Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-KY-413
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.